Monday April 8, 2024
Notice of Full Year Results and Investor Presentation
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Notice of Full Year Results and Investor Presentation Brighton, United Kingdom – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology […]
Wednesday January 31, 2024
Clinical development update
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Clinical development update Positive Results from XF-73 Dermal Safety Study XF-73 Dermal to be progressed towards clinical evaluation for the treatment of […]
Monday January 22, 2024
Appointment of Nominated Adviser and Sole Broker
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Appointment of Nominated Adviser and Sole Broker Brighton, United Kingdom ‐ 22 January 2024 ‐ Destiny Pharma (AIM: DEST), a clinical stage […]
Thursday January 4, 2024
Year End Business Update
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Year End Business Update Brighton, United Kingdom – 4 January 2024 – Destiny Pharma plc (AIM:DEST), a clinical stage biotechnology company focused on the […]
Tuesday October 17, 2023
XF Pipeline Update Meeting
Destiny Pharma plc (“Destiny Pharma” or “the Company”) XF Pipeline Update Meeting with Leading Experts and New Microbiological Data on XF-73 Brighton, United Kingdom – 17 October 2023 – Destiny […]
Tuesday October 17, 2023
Publication of new microbiological data for XF-73
Destiny Pharma plc (“Destiny Pharma” or “the Company”) New publication shows XF‐73 drug potent against 2,527 Staphylococcus isolates Largest study of its kind to date demonstrates effectiveness of XF‐73 against […]
Wednesday September 27, 2023
Notice of XF Pipeline Update Meeting
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Notice of XF Pipeline Update Meeting Brighton, United Kingdom – 27 September 2023 – Destiny Pharma plc (AIM:DEST), a clinical stage biotechnology company focused […]
Wednesday September 20, 2023